0GT.F STOKE THERAPEUT.DL-001

Healthcare Biotechnology Frankfurt Exchange
24.19 EUR
Close of Nov 11, 2026
19.71 32.80
Market cap
EUR 1.58B
P/E
-
P/B
5.05x
ROE
-70.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0GT.F undervalued?

Graham number

The Graham number of STOKE THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

STOKE THERAPEUT.DL-001 fundamental analysis

No fundamental analysis for STOKE THERAPEUT.DL-001 yet.

STOKE THERAPEUT.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About STOKE THERAPEUT.DL-001

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001),…

Full company profile